EXECUTIVE ENGAGEMENTS
POOL
586
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
117
Interactions with Platform & by Email
PARTICIPANTS
23
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
34
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
72
PAGES
136
EDITION
7
PRICE
USD 5600
CODE
MCP21002
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for 3D Bioprinting estimated at US$768.9 Million in the year 2020, is projected to reach a revised size of US$2.8 Billion by 2027, growing at a CAGR of 20.4% over the analysis period 2020-2027. Living Cells, one of the segments analyzed in the report, is projected to record a 22.6% CAGR and reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hydrogels segment is readjusted to a revised 20.7% CAGR for the next 7-year period.
The 3D Bioprinting market in the U.S. is estimated at US$228.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$479 Million by the year 2027 trailing a CAGR of 19.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.5% and 17.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.
In the global Extracellular Matrices segment, USA, Canada, Japan, China and Europe will drive the 16.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$125.4 Million in the year 2020 will reach a projected size of US$364.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$340.2 Million by the year 2027.
SELECT PLAYERS
3D Bioprinting Solutions; 3D Systems; Advanced Solutions Life Sciences; Allevi Inc.; Aspect Biosystems Ltd.; Bio3D Technologies; Cellink; Cellink Global; Cyfuse Biomedical K.K.; Digilab, Inc.; Envisiontec; Gesim; Inventia Life Science Pty Ltd.; Materialise NV; Nano3D Biosciences, Inc.; Oceanz 3D printing & Additive Manufacturing; Organovo Holdings, Inc.; Poietis; Regemat 3D S.L.; Regenhu; Regenovo Biotechnology Co., Ltd.; Rokit Healthcare; Solidscape; Stratasys Ltd.; Tevido Biodevices; Vivax Bio, LLC; Voxeljet
SEGMENTS
» Material (Living Cells, Hydrogels, Extracellular Matrices, Other Materials) » End-Use (Research Organizations & Academic Institutes, Biopharmaceutical Companies, Hospitals)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for 3D Bioprinting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for 3D Bioprinting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Living Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Living Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Hydrogels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Hydrogels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Extracellular Matrices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Extracellular Matrices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Research Organizations & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Research Organizations & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| USA Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Canada Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Japan Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| China Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for 3D Bioprinting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for 3D Bioprinting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Europe Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| France Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Germany Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Italy Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| UK Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for 3D Bioprinting by Material - Living Cells, Hydrogels, Extracellular Matrices and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for 3D Bioprinting by Material - Percentage Breakdown of Value Sales for Living Cells, Hydrogels, Extracellular Matrices and Other Materials for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for 3D Bioprinting by End-Use - Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for 3D Bioprinting by End-Use - Percentage Breakdown of Value Sales for Research Organizations & Academic Institutes, Biopharmaceutical Companies and Hospitals for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 34 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com